Large-cap Health Care company Genmab A/S has moved -0.2% so far today on a volume of 105,360, compared to its average of 1,512,646. In contrast, the S&P 500 index moved -0.0%.
Genmab A/S trades -39.94% away from its average analyst target price of $31.0 per share. The 8 analysts following the stock have set target prices ranging from $20.0 to $50.0, and on average have given Genmab A/S a rating of buy.
If you are considering an investment in GMAB, you'll want to know the following:
-
Genmab A/S has moved -36.3% over the last year, and the S&P 500 logged a change of 8.1%
-
Based on its trailing earnings per share of 1.76, Genmab A/S has a trailing 12 month Price to Earnings (P/E) ratio of 10.6 while the S&P 500 average is 29.3
-
GMAB has a forward P/E ratio of 13.3 based on its forward 12 month price to earnings (EPS) of $1.4 per share
-
Its Price to Book (P/B) ratio is 0.03 compared to its sector average of 3.53
-
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
-
Based in Copenhagen, the company has 2,682 full time employees and a market cap of $11.99 Billion.